Results 71 to 80 of about 9,343 (245)

Genetic evidence of serum phosphate-independent functions of FGF-23 on bone [PDF]

, 2011
Maintenance of physiologic phosphate balance is of crucial biological importance, as it is fundamental to cellular function, energy metabolism, and skeletal mineralization.
Bergwitz, Clemens, Erben, Reinhold G., Kim, Somi, Lanske, Beate Klara Maria, Razzaque, Mohammed Shawkat, Schüler, Christiane, Sitara, Despina, Taguchi, Takashi   +7 more
core   +1 more source

Targeted Alkaline Phosphatase Therapy Enhances Alveolar Bone Healing in X‐Linked Hypophosphatemia in Mice

Journal of Periodontal Research, EarlyView.
Effects of exogenous tissue‐nonspecific alkaline phosphatase (TNAP) were analyzed in the Hyp mouse model of X‐linked hypophosphatemia (XLH). Maxillary first molars were extracted from wild‐type (WT) and Hyp mice at 6 weeks, and collagen gel ± TNAP was placed in sockets. In one group of Hyp mice, submucosal injections of TNAP or saline were delivered at
Aonjittra Phanrungsuwan, Bella Donnelly, José Luis Millán, Brian L. Foster   +3 more
wiley   +1 more source

Approach to a Child with Hypophosphatemia

Biomolecules
Hypophosphatemia is a rare ion disorder in children, but it carries the risk of serious clinical sequelae in tissues and organs with high energy requirements, such as bone tissue.
Agnieszka Antonowicz, Patryk Lipiński, Michał Popow, Piotr Skrzypczyk   +3 more
doaj   +1 more source

Health-related quality of life of X-linked hypophosphatemia in Spain

Orphanet Journal of Rare Diseases, 2022
Plain English summary X-linked hypophosphatemia (XLH) is a severe inherited disease. It is caused by loss of phosphorus by kidneys. As a result, blood level of phosphorus is low, affectingX-linked hypophosphatemia (XLH) is a severe inherited disease.
M. I. Luis Yanes, M. Diaz-Curiel, P. Peris, C. Vicente, S. Marin, M. Ramon-Krauel, J. Hernandez, J. J. Broseta, L. Espinosa, S. Mendizabal, L. Perez-Sukia, V. Martínez, C. Palazón, J. A. Piñero, M. A. Calleja, J. Espin, R. Arborio-Pinel, G. Ariceta   +17 more
doaj   +1 more source

Hypophosphatemic rickets: Revealing Novel Control Points for Phosphate Homeostasis [PDF]

, 2014
Rapid and somewhat surprising advances have recently been made towards understanding the molecular mechanisms causing heritable disorders of hypophosphatemia.
Econs, Michael J., Hum, Julia M., White, Kenneth E.   +2 more
core   +1 more source

The Role of Wnt Signaling in Age‐Related Alveolar Bone Loss and Regeneration

Journal of Periodontal Research, EarlyView.
The graphical abstract summarizes key signaling pathways involved in bone formation and resorption associated with Wnt signaling across young and aged long bone and jaw tissues. Levels of evidence are indicated as robust, moderate, or emerging, reflecting the current experimental support in each context.
Hsiao H. Sung, Navya Chalamalasetty, Ali Alzainal, Hanlong Liu, Lexuan Wang, Pietra Colacrai Arikita, Ivy C. X. Wei, Hom‐Lay Wang, M. H. J. van den Bosch, Michelle S. Caird, Peter M. van der Kraan, Kenneth M. Kozloff, Esmeralda Blaney Davidson   +12 more
wiley   +1 more source

The Metabolic Bone Disease X-linked Hypophosphatemia: Case Presentation, Pathophysiology and Pharmacology

Life, 2021
The authors present a stereotypical case presentation of X-linked hypophosphatemia (XLH) and provide a review of the pathophysiology and related pharmacology of this condition, primarily focusing on the FDA-approved medication burosumab.
Jon Vincze, Brian W. Skinner, Katherine A. Tucker, Kory A. Conaway, Jonathan W. Lowery, Julia M. Hum   +5 more
doaj   +1 more source

A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575) [PDF]

, 2013
PURPOSE: To establish the recommended phase II dose of the oral γ-secretase inhibitor RO4929097 (RO) in combination with gemcitabine; secondary objectives include the evaluation of safety, tolerability, pharmacokinetics, biomarkers of Notch signaling and
Suzanne Richter, Philippe L. Bedard, Eric Xueyu Chen, Blaise A. Clarke, Ben Tran, Sebastien J. Hotte, Anastasios Stathis, Hal W. Hirte, Albiruni R. A. Razak, Michael Reedijk, Zhuo Chen, Brenda Cohen, Wen-Jiang Zhang, Lisa Wang, S. Percy Ivy, Malcolm J. Moore, Amit M. Oza, Lillian L. Siu, Elaine McWhirter, L Miele, V Bolos, S Jarriault, A Klinakis, P Rizzo, J Dufraine, LK Phng, R Plentz, L Luistro, A Tolcher, J Wu, C Moorsel Van, N Cook, P Carmeliet, EA Eisenhauer, W Zhang, DC Allred, BC Dickson, M Reedijk, JR Strosberg, I Krop, TP Dang, W He   +41 more
core   +3 more sources

A new metabolic path in type 3 rickets

The FEBS Journal, Volume 293, Issue 3, Page 656-659, February 2026.
Rickets, a bone disorder, was historically categorised into either nutritional (vitamin D deficiency) or genetic forms involving loss‐of‐function mutations in mineral metabolism. Recently, a new mechanism, type 3 rickets, was discovered to be caused by a gain‐of‐function mutation in CYP3A4 (Ile301Thr).
Toshiya Senda, Yoshihisa Hirota
wiley   +1 more source

Current concepts in odontohypophosphatasia form of hypophosphatasia and report of two cases [PDF]

, 2016
published_or_final_versio
Qiao, W, Su, Y, Wang, ZY, Zhang, K, Zheng, GS   +4 more
core   +1 more source